Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

被引：157

作者：

Soverini, Simona ^{[1
]}

Colarossi, Sabrina ^{[1
]}

Gnani, Alessandra ^{[1
]}

Castagnetti, Fausto ^{[1
]}

Rosti, Gianantonio ^{[1
]}

Bosi, Costanza ^{[1
]}

Paolini, Stefania ^{[1
]}

Rondoni, Michela ^{[1
]}

Piccaluga, Pier Paolo ^{[1
]}

Palandri, Francesca ^{[1
]}

Giannoulia, Panagiota ^{[1
]}

Marzocchi, Giulia ^{[1
]}

Luatti, Simona ^{[1
]}

Testoni, Nicoletta ^{[1
]}

Iacobucci, Ilaria ^{[1
]}

Cilloni, Daniela ^{[2
]}

Saglio, Giuseppe ^{[2
]}

Baccarani, Michele ^{[1
]}

Martinelli, Giovanni ^{[1
]}

机构：

[1] Univ Bologna, Inst Hematol & Med Oncol L&A Seragnoli, Bologna, Italy

[2] Univ Turin, Dept Clin & Biol Sci, Orbassano, Italy

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 03期

关键词：

chronic myeloid leukemia; acute lymphoblastic leukemia; imatinib; dasatinib; resistance; Bcr-Abl; mutations;

D O I：

10.3324/haematol.10822

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) leukemia has prompted the development of second-generation compounds active against several imatinib-insensitive mutant forms of Bcr-Abl, including dasatinib (BMS-354825; Bristol-Myers Squibb). In order to assess which pre-existent or emerging kinase domain mutations are associated with decreased clinical efficacy of desatinib, we analyzed BCR-ABL kinase sequences before and during treatment in 21 Ph+ patients who failed to respond to or relapsed during dasatinib therapy. In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317.

引用

页码：401 / 404

页数：4

共 18 条

[1] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[2] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[3] Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance [J].

Burgess, MR ;

Skaggs, BJ ;

Shah, NP ;

Lee, FY ;

Sawyers, CL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (09) :3395-3400

[4] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

[5] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[6] MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation [J].

Giles, Francis J. ;

Cortes, Jorge ;

Jones, Dan ;

Bergstrom, Donald ;

Kantarjian, Hagop ;

Freedman, Steven J. .

BLOOD, 2007, 109 (02) :500-502

[7]

Martinelli G, 2005, HAEMATOLOGICA, V90, P534

[8] Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP) [J].

Nicolini, F. E. ;

Corm, S. ;

Le, Q. -H. ;

Sorel, N. ;

Hayette, S. ;

Bories, D. ;

Leguay, T. ;

Roy, L. ;

Giraudier, S. ;

Tulliez, M. ;

Facon, T. ;

Mahon, F. -X. ;

Cayuela, J. -M. ;

Rousselot, P. ;

Michallet, M. ;

Preudhomme, C. ;

Guilhot, F. ;

Roche-Lestienne, C. .

LEUKEMIA, 2006, 20 (06) :1061-1066

[9] In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants [J].

O'Hare, T ;

Walters, DK ;

Stoffregen, EP ;

Jia, TP ;

Manley, PW ;

Mestan, J ;

Cowan-Jacob, SW ;

Lee, FY ;

Heinrich, MC ;

Deininger, MWN ;

Druker, BJ .

CANCER RESEARCH, 2005, 65 (11) :4500-4505

[10] Molecular response to imatinib in late chronic-phase chronic myeloid leukemia [J].

Rosti, G ;

Martinelli, G ;

Bassi, S ;

Amabile, M ;

Trabacchi, E ;

Giannini, B ;

Cilloni, D ;

Izzo, B ;

De Vivo, A ;

Testoni, N ;

Cambrin, GR ;

Bonifazi, F ;

Soverini, S ;

Luatti, S ;

Gottardi, E ;

Alberti, D ;

Pane, F ;

Salvatore, F ;

Saglio, G ;

Baccarani, M .

BLOOD, 2004, 103 (06) :2284-2290

← 1 2 →